INTENSITY THERAPEUTICS Business Summary

Intensity Therapeutics, Inc. (INTS) is a late-stage clinical biotechnology company that operates on a research-and-development business model, currently generating capital through strategic equity offerings, at-the-market (ATM) programs, and potential future milestone payments from pharmaceutical collaborations. The company’s primary business segments are centered on its proprietary DIVE (Drug Infiltration and Vascular Exhaustion) platform, which utilizes a non-covalent drug-conjugation technology to deliver cytotoxic agents directly into solid tumors. Its lead candidate, INT230-6, is currently being evaluated in the INVINCIBLE-3 Phase 3 trial for soft tissue sarcoma and the INVINCIBLE-4 Phase 2 trial for triple-negative breast cancer. In the competitive landscape of intratumoral and targeted oncology, Intensity Therapeutics competes with firms such as Aura Biosciences, ALX Oncology, Zymeworks, and Replimune, positioning itself as a niche developer of therapies designed to induce systemic anti-cancer immune responses through localized injection. The company is led by Founder, President, and CEO Lewis H. Bender, who brings over 28 years of industry experience, including previous roles as CEO of Interleukin Genetics and an executive at Emisphere Technologies. Supporting the financial strategy is CFO Joseph Talamo, a seasoned biopharmaceutical executive who formerly served as CFO at HiberCell and Caladrius Biosciences. The leadership team is complemented by a board of directors featuring prominent industry figures, including Dr. Emer Leahy (CEO of PsychoGenics), Daniel J. Donovan (CEO of rareLifeSolutions), and Thomas I. H. Dubin (former Chief Legal Officer of Alexion Pharmaceuticals). As of early 2026, the company continues to leverage its clinical validation and institutional investor support to extend its operational runway through the second quarter of 2027 while seeking to regain Nasdaq listing compliance.